SABCS: Two Years of Anastrozole Sufficient in HR+ Early Breast CA

Share this content:
SABCS: Two Years of Anastrozole Sufficient in HR+ Early Breast CA
SABCS: Two Years of Anastrozole Sufficient in HR+ Early Breast CA

THURSDAY, Dec. 7, 2017 (HealthDay News) -- For women with hormone-receptor positive early breast cancer, comparable benefit is seen with receiving the aromatase inhibitor anastrozole for two years and five years after an initial five years of adjuvant endocrine therapy, according to a study presented at the annual San Antonio Breast Cancer Symposium, held from Dec. 5 to 9 in Texas.

Michael Gnant, M.D., from the Medical University of Vienna, and colleagues randomized 3,484 women with postmenopausal stage I to III hormone-receptor positive early breast cancer to receive two or five years of additional anastrozole as extended adjuvant therapy, after five years of adjuvant endocrine therapy. Patients were followed for a median of 105.9 months after randomization.

The researchers recorded 757 disease-free survival (DFS) events as of June 30, 2016; 22 percent each in the two-year and five-year groups. No significant difference was seen in DFS (hazard ratio, 0.997; 95 percent confidence interval, 0.86 to 1.15; P = 0.982), or in overall survival, time to secondary carcinoma, and time to contralateral breast cancer. In the two-year and five-year arms, 81.2 and 80.1 percent of patients were still taking the study drug at two years, respectively; 65.6 percent of patients were still on assigned medication at five years in the five-year arm.

"There is simply no rationale to keep most patients on extended aromatase inhibitor for longer than two years," Gnant said in a statement.

The study was funded by AstraZeneca, which manufactures anastrozole.

Press Release
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

ASH: Anti-CD19 CAR T-Cell Tx Beneficial in B-Cell Lymphomas

ASH: Anti-CD19 CAR T-Cell Tx Beneficial in B-Cell ...

Second study shows benefit in relapsed or refractory B-cell lymphoma, follicular lymphoma

ASH: AAVD Beats ABVD for Advanced Hodgkin's Lymphoma

ASH: A+AVD Beats ABVD for Advanced Hodgkin's Lymphoma

Lower combined risk of progression, death, or noncomplete response with A+AVD

ASH: High-Dose Gene Transfer Beneficial in Severe Hemophilia A

ASH: High-Dose Gene Transfer Beneficial in Severe Hemophilia ...

Factor VIII gene transfer tied to sustained normalization of factor VIII activity levels

is free, fast, and customized just for you!

Already a member?

Sign In Now »